RxDoctor Payments DataLook up a doctor →

Sashi Makam, MD

Internal Medicine · New Windsor, NYNPI 1861494908

Payments from drug & device makers

$6,165,893in general payments, 2019–2025

Across 2,750 payments — averaging $2242.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • Pfizer$924K
  • Genentech, Inc.$748K
  • Novo Nordisk AS$658K
  • AstraZeneca$641K
  • Sanofi US Services Inc.$506K
  • plus $1.6M from 54 others
$13,835in research payments, 2019–2025

Across 5 payments — averaging $2766.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$8K
  • Eli Lilly$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly22$1,098,065
Pfizer128$924,090
Genentech, Inc.69$748,131
Novo Nordisk AS812$658,490
AstraZeneca164$641,268
Sanofi US Services Inc.73$505,672
Merck187$426,360
AbbVie(2 entities)131$226,640
Amgen97$216,642
GSK180$172,727
Novartis54$133,323
Astrazeneca UK Limited1$88,966
Otsuka Pharmaceutical Development & Commercialization, Inc.6$69,123
Chiesi USA, Inc.26$55,587
Teva Pharmaceuticals USA, Inc.36$38,352
E.r. Squibb & Sons, L.L.C.3$34,241
Adaptive Biotechnologies Corporation1$20,723
Alnylam Pharmaceuticals Inc.3$18,459
Esperion Therapeutics, Inc.36$17,438
Sanofi8$14,557
Bristol Myers Squibb1$14,500
Verona Pharma, Inc.2$11,852
Ferring Pharmaceuticals AS6$10,838
Kowa Research Institute, Inc.3$3,739
Novo Nordisk174$2,797
Ferring International Pharmascience Center US2$2,472
Lilly USA, LLC121$1,714
Boehringer Ingelheim49$1,200
Abbott40$921
Sanofi-aventis U.S. LLC26$909
Johnson & Johnson33$849
Bayer41$813
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC32$519
Amarin Pharma, Inc.26$515
Avanir Pharmaceuticals, Inc.20$478
Exact Sciences20$433
Kowa Pharmaceuticals America, Inc.19$263
Otsuka America Pharmaceutical, Inc.7$231
Antares Pharma, Inc.14$204
Currax Pharmaceuticals LLC12$189
Jazz Pharmaceuticals Inc.5$181
Impulse Dynamics (USA) Inc.1$160
Mylan Specialty L.p.3$135
Viatris Specialty LLC1$125
Insulet Corporation5$110
Dexcom, Inc.4$85
Medtronic3$72
Eisai Inc.3$69
Idorsia Pharmaceuticals US Inc4$66
Acerus Pharmaceuticals Corporation4$64
Regeneron Healthcare Solutions, Inc.4$59
Phathom Pharmaceuticals, Inc.3$52
Axsome Therapeutics, Inc.3$50
Takeda Pharmaceuticals U.S.A., Inc.3$48
Astellas Pharma US Inc2$47
Corcept Therapeutics2$44
IBSA Pharma Inc.2$30
Baxter Healthcare1$30
Seqirus USA Inc2$29
Paratek Pharmaceuticals, Inc.2$29

How this compares

$6,165,893 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Medicare billing

Part B allowed, 2024
$437,741
Medicare patients
552
Services billed
9,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in New Windsor

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →